We-S15:2 Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The field study, a randomised controlled trial
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
More recent trials HPS2-Thrive, FIELD, and ACCORD failed to achieve a statistically significant reduction in their primary end points.
“more recent trials such as the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-Thrive), 59 the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), 60 and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 61 failed to achieve a statistically significant reduction in their primary end points”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [59]
In FIELD, over 5-year follow-up, 5.9% of patients on placebo and 5.2% of those on fenofibrate had a coronary event (relative reduction 11%; HR 0.89; 95% CI 0.75-1.05; P = 0.16).
“Over the 5-year follow-up, 5.9% of patients on placebo and 5.2% of those on fenofibrate had a coronary event (relative reduction of 11%; HR: 0.89; 95% CI: 0.75-1.05; P = 0.16).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [34]
Fenofibrate was associated with less albuminuria progression (P = 0.002) and less retinopathy needing laser treatment (5.2% vs 3.6%; P = 0.0003).
“Fenofibrate was associated with less albuminuria progression (P = 0.002) and less retinopathy needing laser treatment (5.2% vs 3.6%; P = 0.0003), which has prompted some use of this drug for prevention of microvascular complications in patients with type 2 diabetes and elevated triglycerides and/or low HDL-C.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [34]
In FIELD, there was a significant 24% reduction in nonfatal MI (HR 0.76; 95% CI 0.62-0.94; P = 0.010) and a nonsignificant increase in coronary heart disease mortality (HR 1.19; 95% CI 0.90-1.57; P = 0.22).
“There was a significant 24% reduction in nonfatal MI (HR: 0.76; 95% CI: 0.62-0.94; P = 0.010) and a nonsignificant increase in coronary heart disease mortality (HR: 1.19; 95% CI: 0.90-1.57; P = 0.22).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [34]
Cites
Still being checked.
Cited by
Sorted by citations
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,489 · see citing works
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483 · see citing works
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749 · see citing works
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 724 · see citing works
Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 519 · see citing works
Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341 · see citing works
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C. R., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253 · see citing works
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233 · see citing works
2018 Guidelines for the management of dyslipidemia
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 217 · see citing works
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189 · see citing works
Self-citationUpdates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy
Tomita, Y., Lee, D., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204666 · Cited by 104 · see citing works
Vesa, C. M., Popa, L., Popa, A. R., Rus, M., Zaha, A. A., BUNGAU, S. G., Ţiţ, D. M., Aron, R. A. C., & Zaha, D. C. (2020) · Diagnostics · doi:10.3390/diagnostics10050314 · Cited by 98 · see citing works
The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Bernardi, S., Marcuzzi, A., Piscianz, E., Tommasini, A., & Fabris, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124058 · Cited by 71 · see citing works
Chiu, H., Tsai, H.-J., Huang, J., Wu, P.-Y., Hsu, W., Lee, M., & Chen, S. (2020) · Nutrients · doi:10.3390/nu12020328 · Cited by 65 · see citing works
The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity
Karwi, Q. G., Sun, Q., & Lopaschuk, G. D. (2021) · Cells · doi:10.3390/cells10113259 · Cited by 65 · see citing works
Effects of High Glucose and Lipotoxicity on Diabetic Podocytes
Nakamichi, R., Hayashi, K., & Itoh, H. (2021) · Nutrients · doi:10.3390/nu13010241 · Cited by 59 · see citing works
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48 · see citing works
Hadjivasilis, A., Kouis, P., Kousios, A., & Panayiotou, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030768 · Cited by 46 · see citing works
The role of fenofibrate in clinical practice
Zambon, A., & Cusi, K. J. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.053 · Cited by 40 · see citing works
PPARs and Myocardial Infarction
Wagner, K., & Wagner, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249436 · Cited by 40 · see citing works
Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 24 · see citing works
Lipid‐lowering therapy in patients with type 2 diabetes: the case for early intervention
Steinmetz, A. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.806 · Cited by 20 · see citing works
Simes, J. R., Voysey, M., O'Connell, R. L., Glasziou, P., Best, J. D., Scott, R. S., Pardy, C. J., Byth, K., SULLIVAN, D. R., Ehnholm, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008580 · Cited by 19 · see citing works
Self-citationAomura, D., Harada, M., Yamada, Y., Nakajima, T., Hashimoto, K., Tanaka, N., & Kamijo, Y. (2021) · Metabolites · doi:10.3390/metabo11060372 · Cited by 20 · see citing works
Changes in Cardiac Metabolism in Prediabetes
de Wit‐Verheggen, V. H. W., & van de Weijer, T. (2021) · Biomolecules · doi:10.3390/biom11111680 · Cited by 17 · see citing works
PPARα Modulation-Based Therapy in Central Nervous System Diseases
Lee, D., Tomita, Y., Allen, W., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · Life · doi:10.3390/life11111168 · Cited by 17 · see citing works
Optimal management of lipids in diabetes and metabolic syndrome
Brown, W. V., Clark, L. T., Falko, J. M., Guyton, J. R., Rees, T., Schonfeld, G., & Lopes-Virella, M. F. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.08.444 · Cited by 16 · see citing works
Мусина, Н. Н., Саприна, Т. В., Prokhorenko, T. S., Kanev, A. F., & Zima, A. P. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030070 · Cited by 14 · see citing works
Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
Temporelli, P. L., Arca, M., D’Erasmo, L., & Caterina, R. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040886 · Cited by 10 · see citing works
Tian, S., Wang, R., Chen, S., He, J.-L., Zheng, W., & Li, Y. (2021) · Molecules · doi:10.3390/molecules26196012 · Cited by 8 · see citing works
Flores‐Castillo, C., Luna‐Luna, M., Carreón‐Torres, E., López‐Olmos, V., Frı́as, S., Juárez-Oropeza, M. A., Franco, M., Fragoso, J. M., Vargas‐Alarcón, G., & Pérez-Méndez, O. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102521 · Cited by 8 · see citing works
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 6 · see citing works
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6 · see citing works
Palmisano, B. T., Zhu, L., Litts, B., Burman, A., Yu, S., Neuman, J. C., Anozie, U., Luu, T. N., Edington, E. M., & Stafford, J. M. (2021) · Metabolites · doi:10.3390/metabo11050330 · Cited by 5 · see citing works
Zhou, Q., Ren, D., Xiao, Y., Yi, L., & Zhou, Z. (2019) · RSC Advances · doi:10.1039/c9ra07634d · Cited by 2 · see citing works
Steiner, G. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2011.12.001
Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes
Pedro‐Botet, J. (2008) · The British Journal of Diabetes · doi:10.1177/14746514080080010601
- Authors
- Keech, A., & Field Study Investigators
- ORCID
- Keech, A.
- Venue
- Atherosclerosis Supplements
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 7
- Issue
- 3
- Pages
- 342
- ISSN
- 1567-5688 (ISSN-L)
- OpenAlex
- W2151221752
- Cited by
- 28
- References
- 0
- Citations by year
- 2021: 11 · 2020: 4 · 2019: 4 · 2018: 3 · 2012: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Atherosclerosis Supplements (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- fenofibrate, type 2 diabetes, cardiovascular events, long-term treatment, lipid-lowering therapy, cardiovascular risk reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
